Phathom Pharmaceuticals, Inc.2024财年第二财季实现净利润-91.45百万美元，同比减少123.21%

自选股智能写手08-17

8月17日，Phathom Pharmaceuticals, Inc.（PHAT.US）公布财报，公告显示公司2024财年第二财季净利润为-91.45百万美元，同比减少123.21%；其中营业收入为7.32百万美元，每股基本收益为-1.56美元。从资产负债表来看，Phathom Pharmaceuticals, Inc.（PHAT.US）总负债5.53亿美元，其中短期债务10.63百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460241318?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460241318","market":"us","top_or_hot":-1,"title":"Phathom Pharmaceuticals, Inc.2024财年第二财季实现净利润-91.45百万美元，同比减少123.21%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Phathom Pharmaceuticals, Inc.（PHAT.US）公布财报，公告显示公司2024财年第二财季净利润为-91.45百万美元，同比减少123.21%；其中营业收入为7.32百万美元，每股基本收益为-1.56美元。从资产负债表来看，Phathom Pharmaceuticals, Inc.（PHAT.US）总负债5.53亿美元，其中短期债务10.63百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006329f31b1b9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phathom Pharmaceuticals, Inc.2024财年第二财季实现净利润-91.45百万美元，同比减少123.21%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhathom Pharmaceuticals, Inc.2024财年第二财季实现净利润-91.45百万美元，同比减少123.21%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006329f31b1b9&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Phathom Pharmaceuticals, Inc.（PHAT.US）公布财报，公告显示公司2024财年第二财季净利润为-91.45百万美元，同比减少123.21%；其中营业收入为7.32百万美元，每股基本收益为-1.56美元。从资产负债表来看，Phathom Pharmaceuticals, Inc.（PHAT.US）总负债5.53亿美元，其中短期债务10.63百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006329f31b1b9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006329f31b1b9&s=b","article_id":"2460241318","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170006329f31b1b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460241318","pubTimestamp":1723824039,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Phathom Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第二财季净利润为-91.45百万美元，同比减少123.21%；其中营业收入为7.32百万美元，每股基本收益为-1.56美元。机构评级：截至2024年8月17日，当前有7家机构对Phathom Pharmaceuticals, Inc.目标价做出预测，其中目标均价为22.57美元，其中最低目标价为12.00美元，最高目标价为28.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PHAT":"Phathom Pharmaceuticals"},"translate_title":"Phathom Pharmaceuticals, Inc. achieved net profit of-US $91.45 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 123.21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"8月17日，Phathom Pharmaceuticals, Inc.（PHAT.US）公布财报，公告显示公司2024财年第二财季净利润为-91.45百万美元，同比减少123.21%；其中营业收入为7.32百万美元，每股基本收益为-1.56美元。从资产负债表来看，Phathom Pharmaceuticals, Inc.（PHAT.US）总负债5.53亿美元，其中短期债务10.63百万美元，资产负债比为0.58，流动比率为0.07。机构评级：截至2024年8月17日，当前有7家机构对Phathom Pharmaceuticals, Inc.目标价做出预测，其中目标均价为22.57美元，其中最低目标价为12.00美元，最高目标价为28.00美元。公司简介：Phathom Pharmaceuticals Inc 是一家临床阶段的生物制药公司。 该公司专注于开发和商业化胃肠道疾病的新型疗法。 它的产品由vonoprazan（一种口服的小分子钾竞争性酸阻滞剂）组成，可阻断胃酸的分泌。 Vonoprazan具有快速， 有效和持久的抗分泌作用，并已证明在治疗胃食管反流疾病以及与抗生素联合治疗幽门螺杆菌感染方面具有临床效益。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460241318"}